A Cell Culture (Vero)–Derived H5N1 Whole-Virus Vaccine Induces Cross-Reactive Memory Responses

Novel strategies are required to provide rapid vaccine coverage in the event of an influenza pandemic. A phase I/II dose finding/formulation study was performed with a whole-virus H5N1 clade 1 A/Vietnam vaccine (2-dose priming regimen) to evaluate safety and immunogenicity. Seventy-seven of 141 subj...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases 2009-10, Vol.200 (7), p.1113-1118
Main Authors: Ehrlich, Hartmut J., Müller, Markus, Fritsch, Sandor, Zeitlinger, Markus, Berezuk, Greg, Löw-Baselli, Alexandra, van der Velden, Maikel V. W., Pöllabauer, Eva Maria, Maritsch, Friedrich, Pavlova, Borislava G., Tambyah, Paul A., Oh, Helen M. L., Montomoli, Emanuele, Kistner, Otfried, Noel Barrett, P.
Format: Article
Language:English
Subjects:
Animals
Antibodies
Antibodies, Viral
Applied microbiology
Biological and medical sciences
Cercopithecus aethiops
Dosage
Dose-Response Relationship, Immunologic
Fundamental and applied biological sciences. Psychology
H5N1 subtype influenza A virus
Hemolysis
Humans
Immune response
Immunity
Immunization, Secondary
Immunologic Memory
Infectious diseases
Influenza A Virus, H5N1 Subtype - immunology
Influenza Vaccines - administration & dosage
Influenza Vaccines - immunology
Influenza, Human - prevention & control
Medical sciences
Microbiology
Miscellaneous
Neutralizing antibodies
Pandemics
Vaccination
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
Vero Cells
Virology
Viruses
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Novel strategies are required to provide rapid vaccine coverage in the event of an influenza pandemic. A phase I/II dose finding/formulation study was performed with a whole-virus H5N1 clade 1 A/Vietnam vaccine (2-dose priming regimen) to evaluate safety and immunogenicity. Seventy-seven of 141 subjects in this study received a booster (12–17 months after priming) with a 7.5-μg dose of a clade 2.1 A/Indonesia vaccine. The prime-boost regimen resulted in antibody responses against clade 1, 2.1, 2.2, and 2.3 viruses that were significantly higher than those after the priming regimen. These findings demonstrate that a prime-boost regimen may alleviate vaccine supply constraints in a pandemic Clinical trials registrationNCT00530660
ISSN:0022-1899
1537-6613
DOI:10.1086/605608